Crinetics Pharmaceuticals, Inc.
CRNXDelisted Sep 1, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658247
Crinetics Pharmaceuticals, Inc. was delisted on Sep 1, 2026; its insiders filed their last Form 4 on Sep 1, 2026; 267 institutions reported holding it in 13F filings for Q2 2026, worth $4.63B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Crinetics Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $120.0K in total
- Insiders trading
- 1
- Net value
- −$120.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Crinetics Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Wierenga Wendell | Director | 0 | Sep 1, 2026 | 2 |
| Vivaldi Coelho Rogerio | Director | 0 | Sep 1, 2026 | 4 |
| Okey Stephanie | Director | 0 | Sep 1, 2026 | 4 |
| Nichols Weston | Director | 0 | Sep 1, 2026 | 2 |
| Fust Matthew K | Director | 0 | Sep 1, 2026 | 3 |
| Deardorf Caren | Director | 0 | Sep 1, 2026 | 2 |
| Bedrosian Camille L | Director | 0 | Sep 1, 2026 | 2 |
| Kalofonos Isabel | Chief Commercial Officer | 0 | Sep 1, 2026 | 3 |
| Betz Stephen F. | Chief Scientific Officer | 0 | Sep 1, 2026 | 4 |
| Schilke Tobin | Chief Financial & Infra. Ofcr. | 0 | Sep 1, 2026 | 4 |
| Struthers Richard Scott | President & CEO | 0 | Sep 1, 2026 | 7 |
| Knight Jeff E. | Chief Dev. & Operating Officer | 105,289 | Apr 10, 2026 | 3 |
| Pizzuti Dana | Chief Med and Dev Officer | 66,837 | Dec 3, 2025 | 3 |
| Wierenga Wendall | Director | 116,146 | Jun 13, 2025 | 0 |
| Wilson Marc | CFO | 111,092 | Sep 30, 2024 | 0 |
| Hassard James | Chief Commercial Officer | 29,259 | Jul 9, 2024 | 0 |
| Krasner Alan Seth | Chief Medical Officer | 43,210 | Oct 19, 2023 | 0 |
| Edelman Joseph | 10% Owner | 5,321,032Indirect | Apr 18, 2022 | 0 |
| Perceptive Advisors LLC | 10% Owner | 5,321,032Indirect | Apr 18, 2022 | 0 |
| Perceptive Life Sciences Master Fund Ltd | 10% Owner | 5,321,032Indirect | Apr 18, 2022 | 0 |
| Madan Ajay | Chief Development Officer | 176,995 | Mar 2, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 20, 2022 (view filing) | Jan 18 | 2 days | Betz Stephen F.Chief Scientific Officer | SSale | −4.17K | $23.29 | −$97.1K | −3.1%128.9K after | |
| Jan 6, 2022 (view filing) | Jan 3 | 3 daysLate | Betz Stephen F.Chief Scientific Officer | SSale | −7.17K | $28.02 | −$200.8K | −5.1%133.0K after | |
| Dec 30, 2021 (view filing) | Dec 28 | 2 days | Betz Stephen F.Chief Scientific Officer | SSale | −3.00K | $27.95 | −$83.8K | −2.1%140.2K after | |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Betz Stephen F.Chief Scientific Officer | SSale | −5.67K | $24.14 | −$136.8K | −3.8%143.2K after | |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Betz Stephen F.Chief Scientific Officer | SSale | −5.67K | $27.38 | −$155.2K | −3.7%148.9K after | |
| Nov 17, 2021 (view filing) | Nov 15 | 2 days | Betz Stephen F.Chief Scientific Officer | SSale | −5.67K | $26.75 | −$151.6K | −3.5%156.0K after | |
| Nov 17, 2021 (view filing) | Nov 16 | 1 day | Betz Stephen F.Chief Scientific Officer | SSale | −1.50K | $27.97 | −$42.0K | −1.0%154.5K after | |
| Nov 9, 2021 (view filing) | Nov 5-8 | 4 days | Betz Stephen F.Chief Scientific Officer | SSale | −16.5K | $28.06 | −$463.0K | −9.3%161.7K after | 2 lots |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Betz Stephen F.Chief Scientific Officer | SSale | −5.67K | $24.79 | −$140.5K | −3.1%178.2K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Fust Matthew KDirector | SSale | −8.95K | $25.50 | −$228.3K | −41.7%12.5K after | |
| Oct 28, 2021 (view filing) | Oct 27 | 1 day | Betz Stephen F.Chief Scientific Officer | SSale | −3.00K | $24.00 | −$72.0K | −1.6%183.9K after | |
| Oct 25, 2021 (view filing)2:47 PM ET | Oct 25 | Same day | Edelman Joseph and 2 others10% Owner | PPurchase | +1.20M | $19.80 | +$23.8M | +30.3%5.16M after | |
| Oct 25, 2021 (view filing) | Oct 21 | 4 days | Betz Stephen F.Chief Scientific Officer | SSale | −1.04K | $21.10 | −$22.0K | −0.6%186.9K after | |
| Sep 9, 2021 (view filing) | Sep 8 | 1 day | Fust Matthew KDirector | SSale | −6.05K | $25.50 | −$154.2K | −32.5%12.5K after | |
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Struthers Richard ScottPresident & CEO | SSale | −30.0K | $25.00 | −$750.0K | −25.0%90.0K after | 3 lots |
| Jul 27, 2021 (view filing) | Jul 26 | 1 day | Fust Matthew KDirector | SSale | −5.00K | $19.59 | −$98.0K | −28.5%12.5K after | |
| Jul 20, 2021 (view filing) | Jul 19 | 1 day | Fust Matthew KDirector | SSale | −5.00K | $19.50 | −$97.5K | −28.5%12.5K after | |
| Jul 13, 2021 (view filing) | Jul 12 | 1 day | Fust Matthew KDirector | SSale | −5.00K | $20.71 | −$103.5K | −28.5%12.5K after |